FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 559 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Most Cases of Venous Thromboembolic Events, Elevated Aminotransferases, and Interstitial Lung... May 8, 2021 Sun Safety May 20, 2022 EMA Recommends Extension of Indications for Pirtobrutinib April 24, 2025 4 Ways to Manage Setbacks in Your Cancer Recovery: A Young... April 11, 2023 Load more HOT NEWS FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung... Teacher Reads To Students One Day After Having Brain Surgery Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer Withdrawal of the Application to Change the EMA Marketing Authorisation for...
